Drugs /

adct-601

Back to Drugs List

Overview

NCI Definition [1]:
An antibody-drug conjugate (ADC), consisting of a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against AXL receptor tyrosine kinase (AXL; UFO) that is site-specifically conjugated to PL1601, which contains a valine-alanine cleavable linker and SG3199, a cytotoxic pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of anti-AXL/PBD antibody-drug conjugate ADCT-60 binds to AXL, which is expressed on the surfaces of a variety of cancer cell types. Upon endocytosis and enzymatic cleavage, free PBD is released and forms highly cytotoxic DNA interstrand cross-links, thereby blocking cell division and killing AXL-expressing cancer cells. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases, is overexpressed by many tumor cell types, and plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.

Clinical Trials

View Clinical Trials for adct-601

Adct-601 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating adct-601, 1 is phase 1 (0 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for adct-601 clinical trials.

Breast carcinoma, colorectal carcinoma, and esophageal carcinoma are the most common diseases being investigated in adct-601 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Adct-601
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating adct-601 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-axl/pbd antibody-drug conjugate adct-601, bgb601, bgb-601, bgb 601, anti-axl/pbd adc adct-601
Drug Target(s) [2]:
AXL
NCIT ID [1]:
C160890

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.